Measures · D14 in 2021 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Statin Use in Persons with Diabetes (SUPD)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- To lower their risk of developing heart disease, most people with diabetes should take cholesterol medication. This rating is based on the percent of plan members with diabetes who take the most effective cholesterol-lowering drugs. Plans can help make sure their members get these prescriptions filled.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 40-75 years old who were dispensed at least two diabetes medication fills and received a statin medication fill during the measurement period. The percentage is calculated as the number of member-years of enrolled beneficiaries 40-75 years old who received a statin medication fill during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 40-75 years old with at least two diabetes medication fills during the measurement period (denominator). The SUPD measure is adapted from the measure concept that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The SUPD measure is calculated using the National Drug Code (NDC) lists updated by the PQA. The complete NDC lists, including diagnosis codes, are posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from Prescription Drug Event (PDE) data submitted by drug plans to Medicare for dates of service from January 1, 2019-December 31, 2019, and processed by June 30, 2020. Only final action PDE claims are used to calculate the patient safety measures. PDE adjustments made post-reconciliation were not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), the Common Working File (CWF), and the Risk Adjustment Processing System (RAPS). • CME is used for enrollment information. • EDB is used for hospice enrollment and ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes • RAPS is used for diagnosis information, RxHCC - Dialysis Status (most recent available Payment Year)
- Measurement period
- 01/01/2019 – 12/31/2019
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator). The following beneficiaries are excluded from the denominator if at any time during the measurement period: • Hospice enrollment • ESRD diagnosis or dialysis coverage dates- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. Also, the member- years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member years for each episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12).
- Disaster policy
- Higher measure star (2020-2021) for contracts with 25% or more enrolled affected by 2019 disasters.
From the 2021 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 83 | 84.5 | +1.5 |
| 3★ | MA-PD | 87 | 89 | +2 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 94 | 95 | +1 |
| 2★ | PDP | 81 | 82.5 | +1.5 |
| 3★ | PDP | 83 | 83.5 | +0.5 |
| 4★ | PDP | 85 | 85.5 | +0.5 |
| 5★ | PDP | 87 | 88 | +1 |
2021 star distribution
Not rated: Plan too new to be measured (186); Not enough data available (49); No data available (39); Plan not required to report measure (9)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 94 % | >= 94 % |
| 2027 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2026 | MA-PD | < 81 % | >= 81 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2026 | PDP | < 82 % | >= 82 % to < 83 % | >= 83 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2025 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2025 | PDP | < 80 % | >= 80 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2024 | MA-PD | < 81 % | >= 81 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2024 | PDP | < 81 % | >= 81 % to < 83 % | >= 83 % to < 85 % | >= 85 % to < 87 % | >= 87 % |
| 2023 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 86 % | >= 86 % to < 90 % | >= 90 % |
| 2023 | PDP | < 80 % | >= 80 % to < 82 % | >= 82 % to < 84 % | >= 84 % to < 86 % | >= 86 % |
| 2022 | MA-PD | < 76 % | >= 76 % to < 80 % | >= 80 % to < 84 % | >= 84 % to < 88 % | >= 88 % |
| 2022 | PDP | < 77 % | >= 77 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 84 % | >= 84 % |
| 2021 | MA-PD | < 77 % | >= 77 % to < 81 % | >= 81 % to < 83 % | >= 83 % to < 87 % | >= 87 % |
| 2021 | PDP | < 74 % | >= 74 % to < 79 % | >= 79 % to < 82 % | >= 82 % to < 85 % | >= 85 % |
| 2020 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 81% | ? 81% to < 83% | ? 83% |
| 2020 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 79% | ? 79% to < 83% | ? 83% |
| 2019 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 80% | ? 80% to < 83% | ? 83% |
| 2019 | PDP | < 73% | ? 73% to < 77% | ? 77% to < 79% | ? 79% to < 82% | ? 82% |
Lowest-scoring contracts, 2021
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S1894 CommunityCare Prescription Drug Plan (PDP) | St Francis Health System & St John Health System | — | 68 | 1 | — | 14 | 0% |
| H5117 Wellcare | Centene Corporation | 0 | 65 | 1 | — | 18 | 0% |
| H5377 Humana | Humana Inc. | 3,919 | 66 | 1 | — | 17 | 0% |
| H3708 American Health Advantage of Oklahoma | Mitchell Family Office | 549 | 70 | 1 | 0 | 13 | 0% |
| H3206 Presbyterian Insurance Company, Inc. | Presbyterian Healthcare Services | — | 70 | 1 | 0 | 13 | 0% |
| H2591 Health Alliance Medicare | The Carle Foundation | — | 71 | 1 | — | 12 | 1% |
| H6743 ATRIO Health Plans | ATRIO Health Plans | 21,042 | 71 | 1 | 0 | 12 | 1% |
| H2392 Kansas Health Advantage | Kansas Superior Select | 873 | 72 | 1 | — | 11 | 1% |
| R7220 Humana | Humana Inc. | 2,904 | 72 | 1 | −1 | 11 | 1% |
| H4754 PacificSource Medicare | PacificSource | 2,527 | 72 | 1 | 0 | 11 | 1% |
| H7680 Prominence Health Plan | Universal Health Services, Inc. | 25,862 | 73 | 1 | −1 | 10 | 2% |
| H6502 Blue Medicare Advantage | Blue Cross and Blue Shield of Kansas City | — | 73 | 1 | 0 | 10 | 2% |
| H3810 AllCare Advantage | AllCare Health, Inc. | 2,485 | 73 | 1 | −1 | 10 | 2% |
| S5916 Regence BlueShield of Idaho and Regence BC BS Utah | Cambia Health Solutions, Inc. | 1,098 | 74 | 2 | 0 | 8 | 2% |
| H5199 Wellcare | Centene Corporation | — | 74 | 1 | — | 9 | 3% |
| H1099 Health First Health Plans, Inc. | Health First Shared Services, Inc. | 37,197 | 74 | 1 | 0 | 9 | 3% |
| H4198 Integris Health Partners+ (HMO) | St Francis Health System & St John Health System | — | 74 | 1 | 0 | 9 | 3% |
| H1304 Regence BlueShield of Idaho | Cambia Health Solutions, Inc. | 902 | 74 | 1 | 0 | 9 | 3% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 74 | 1 | 0 | 9 | 3% |
| H9811 Wellcare | Centene Corporation | 0 | 74 | 1 | 0 | 9 | 3% |
| R0802 Martin's Point Generations Advantage | Martin's Point Health Care, Inc. | — | 74 | 1 | — | 9 | 3% |
| H1350 Blue Cross of Idaho | Gemstone Holdings, Inc. | 32,406 | 74 | 1 | −1 | 9 | 3% |
| H2161 Upper Peninsula Health Plan | DLP Marquette General Hospital, LLC | — | 74 | 1 | −1 | 9 | 3% |
| H3251 Blue Cross and Blue Shield of New Mexico | Health Care Service Corporation | 19,880 | 74 | 1 | −1 | 9 | 3% |
| H1664 Wellcare | Centene Corporation | 3,614 | 74 | 1 | 0 | 9 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D11 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2025 – 12/31/2025 | 1 | Prescription Drug Events |
| 2026 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2024 – 12/31/2024 | 1 | Prescription Drug Events |
| 2025 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2023 – 12/31/2023 | 1 | Prescription Drug Events |
| 2024 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2022 – 12/31/2022 | 1 | Prescription Drug Events |
| 2023 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2021 – 12/31/2021 | 1 | Prescription Drug Events |
| 2022 | D12 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2018 – 12/31/2018 | 1 | Prescription Drug Events |
| 2019 | D14 | Statin Use in Persons with Diabetes (SUPD) | 01/01/2017 – 12/31/2017 | 1 | Prescription Drug Events |